ArticlePharmaceutical research2010
In vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products.
Article in Pharmaceutical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 80 citations in OpenAlex.
- Simulation of drug transport in airway surface liquid considering mucus flow and ciliary interaction.Scientific reports · 2025Article
- Comparative analysis of drug deposition patterns among three commercial nasal spray brands: A computational and experimental study.Journal of molecular liquids · 2025Article
- Development of a biorelevant dissolution method for inhalation products: Proof of concept using drugs with diverse solubilities.ADMET & DMPK · 2025Article
- Preparation, Optimization andRecent advances in drug delivery and formulation · 2024Article
- In Vitro Dissolution and Permeability Testing of Inhalation Products: Challenges and Advances.Pharmaceutics · 2023Review
- Dissolution and Absorption of Inhaled Drug Particles in the Lungs.Pharmaceutics · 2022Review
- Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB/c Mice with Chronic Mycobacterium tuberculosis Infection.Antimicrobial agents and chemotherapy · 2022Article
- Characterization of Membrane-Type Dissolution Profiles of Clinically Available Orally Inhaled Products Using a Weibull Fit and a Mechanistic Model.Molecular pharmaceutics · 2022Article
- iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System.Molecular pharmaceutics · 2022Review
- Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers.The AAPS journal · 2021Article
- Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats.Pharmaceutics · 2021Article
- Optimization of the TranswellPharmaceutics · 2021Article
- Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process.Pharmaceutics · 2021Review
- Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.Pharmaceutics · 2021Review
- Article
- Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing.Pharmaceutics · 2020Article
- Model for the Analysis of Membrane-Type Dissolution Tests for Inhaled Drugs.Molecular pharmaceutics · 2020Article
- In Vivo-Relevant Transwell Dish-Based Dissolution Testing for Orally Inhaled Corticosteroid Products.Pharmaceutical research · 2019Article
- Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products.Molecular pharmaceutics · 2019Article
- Use of computational fluid dynamics deposition modeling in respiratory drug delivery.Expert opinion on drug delivery · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop a unique in vitro aqueous fluid-capacity-limited dissolution system for the kinetic assessment of respirable aerosol drug particles from inhaler products.
methodsAerosol particles of 5 inhaled corticosteroids (ICSs) from 7 inhaler products were collected in the aerodynamic 2.1-3.3 or 4.7-5.8 mum on the filter membranes using the Andersen cascade impactor. Each filter membrane was then placed onto the donor compartment of the Transwell(R) system, where addition of 0.04ml aqueous fluid initiated aerosol ICS dissolution and permeation across its supporting membrane at 37 degrees C and approximately 100% humidity.
resultsThe % profiles of dissolution and permeation were apparent first-order or pseudo-zero-order, reaching varying 1.9-95.0% by 5 h. Their kinetics overall conformed to the ICS aqueous solubility. With increasing aerosol mass, however, the profiles decelerated, attributed to undissolved ICSs left by the limited dissolution fluid capacity. The profiles could be also product-specific, as beclomethasone dipropionate aerosols from QVAR dissolved faster than those from VANCERIL, whereas fluticasone propionate aerosols from two different inhaler products exhibited comparable profiles. The 2.1-3.3 mum aerosols dissolved faster than the 4.7-5.8 mum aerosols.
conclusionsAerosol ICS dissolution into the limited aqueous fluid volume differed kinetically due to ICS solubility and aerosol mass, size, formulation and/or generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.